Table 2 Clinicopathological characteristics according to VWA5A expression in the validation set.
VWA5A-low | VWA5A-high | Total | p | |
|---|---|---|---|---|
Age (mean ± SD) | 51 ± 11 | 50 ± 10 | 51 ± 10 | |
Subtype | 0.789 | |||
HR+HER2− | 330 (59.6%) | 246 (59.7%) | 576 (59.6%) | |
HR+HER2+ | 20 (7.2%) | 30 (7.3%) | 70 (7.2%) | |
HR−HER2+ | 43 (7.8%) | 40 (9.7%) | 83 (8.6%) | |
TNBC | 98 (17.7%) | 64 (15.5%) | 162 (16.8%) | |
Unknown | 43 (7.8%) | 32 (7.8%) | 75 (7.8%) | |
Nuclear grade | 0.324 | |||
1 | 10 (1.8%) | 7 (1.7%) | 17 (1.8%) | |
2 | 222 (40.1%) | 152 (36.9%) | 374 (38.7%) | |
3 | 322 (58.1%) | 253 (61.4%) | 575 (59.5%) | |
Histologic grade | 0.704 | |||
I | 31 (5.6%) | 22 (5.4%) | 53 (5.5%) | |
II | 211 (38.2%) | 165 (40.1%) | 376 (39.0%) | |
III | 311 (56.2%) | 224 (54.5%) | 535 (55.5%) | |
Lymphatic invasion | 0.009 | |||
Absent | 335 (60.8%) | 280 (69.0%) | 615 (64.3%) | |
Present | 216 (39.2%) | 126 (31.0%) | 342 (35.7%) | |
Distant metastasis | 0.183 | |||
Absent | 524 (94.6%) | 381 (92.5%) | 905 (93.7%) | |
Present | 30 (5.4%) | 31 (7.5%) | 14 (1.4%) | |
pT stage | 0.028 | |||
pT1a | 3 (0.5%) | 7 (1.7%) | 10 (1.0%) | |
pT1b | 26 (4.7%) | 36 (8.7%) | 62 (6.2%) | |
pT1c | 234 (42.2%) | 170 (41.3%) | 404 (41.8%) | |
pT2 | 273 (50.2%) | 187 (45.4%) | 465 (48.1%) | |
pT3 | 13 (2.3%) | 12 (2.9%) | 25 (2.6%) | |
pN stage | 0.481 | |||
pN0 | 355 (64.2%) | 275 (67.4%) | 630 (65.6%) | |
pN1 | 143 (25.9%) | 95 (23.3%) | 238 (24.8%) | |
pN2 | 38 (6.9%) | 24 (5.9%) | 62 (6.5%) | |
pN3 | 17 (3.1%) | 14 (3.4%) | 31 (3.2%) | |
Total | 554 (57.3%) | 412 (42.7%) | 966 (100.0%) | |
